Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group PLC has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Dayforce, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 3.4% of Ardelyx, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting beneficial ownership of 4.7% of OSI Systems, Inc. common stock.

Janus Henderson Group plc has reported a beneficial ownership of 4.9% of Revolution Medicines, Inc. common stock as of March 31, 2026.

Janus Henderson Group plc has reported beneficial ownership of 4,175,982 common shares, representing 4.5% of the class, in Xenon Pharmaceuticals Inc.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 3.5% of SS&C Technologies Holdings, Inc. common stock.

Janus Henderson Group plc has reported beneficial ownership of 1,205,303 common shares, representing 2.3% of the class, in Soleno Therapeutics, Inc. as of April 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 10.1% of Adagene Inc.'s American Depository Receipts, holding 6,666,666 shares.

Janus Henderson Group plc has reported beneficial ownership of 14.4% of Promis Neurosciences Inc. common shares as of March 31, 2026.

Janus Henderson Group plc has reported a beneficial ownership of 10.3% of 4D Molecular Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Janus Henderson Group PLC following an internal realignment, marking a significant change in its reporting structure.

Janus Henderson Group plc has reported a 6.2% beneficial ownership stake in JADE BIOSCIENCES, INC., holding over 3 million shares as of December 31, 2025.

Janus Henderson Group plc has reported a 7.9% beneficial ownership stake in Contineum Therapeutics, Inc. Class A Common Stock as of December 31, 2025.

Janus Henderson Group plc has reported a 7.4% beneficial ownership stake in Immix Biopharma, Inc. common stock as of December 31, 2025.

Janus Henderson Group plc has reported a 5.1% beneficial ownership stake in DraftKings Inc. Class A Common Stock as of December 31, 2025.

Janus Henderson Group plc has reported a 5.3% beneficial ownership stake in Glaukos Corp, holding over 3 million shares.

Janus Henderson Group plc has reported a 5.7% beneficial ownership stake in BridgeBio Pharma, Inc. through its various asset management entities.

Janus Henderson Group plc has reported a 5.9% beneficial ownership stake in Bel Fuse Inc.'s Class B Common Stock.

Janus Henderson Group plc has reported a 6.0% beneficial ownership stake in PTC Therapeutics, Inc., holding 4,851,332 common shares.

Janus Henderson Group plc has reported an 8.1% beneficial ownership stake in 4D Molecular Therapeutics, Inc. common stock.

Janus Henderson Group plc reports 0% beneficial ownership in Vistagen Therapeutics, Inc., signaling a complete divestment of its previous stake.

Janus Henderson Group plc, through its asset managers, reported a 4.9% beneficial ownership stake in Sensient Technologies Corporation as of December 31, 2025.

Janus Henderson Group plc has reported a 3.1% beneficial ownership stake in Metsera, Inc. common stock through its various asset managers.

Janus Henderson Group plc filed an amended Schedule 13G, reporting a 0.0% beneficial ownership in Mereo Biopharma Group PLC as of December 31, 2025.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting a reduced beneficial ownership of 4.1% in Akero Therapeutics, Inc.

Janus Henderson Group plc has filed an amendment to its Schedule 13G, reporting beneficial ownership of 1.9% of Avadel Pharmaceuticals PLC's ordinary shares as of December 31, 2025.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 4.6% beneficial ownership stake in Avidity Biosciences, Inc. as of December 31, 2025.

Janus Henderson Group plc has reported a 9.99% beneficial ownership stake in Equillium, Inc., primarily through its asset management subsidiaries.

Janus Henderson Group plc has reported a 10.1% beneficial ownership stake in Relmada Therapeutics, Inc., holding 7,439,415 shares of common stock.

Janus Henderson Group plc has reported a 12.7% beneficial ownership stake in Biohaven Ltd., holding 16,803,459 common shares.